Company Website:
http://www.exelixis.com
SOUTH SAN FRANCISCO, Calif. -- (Business Wire)
Exelixis, Inc. (NASDAQ: EXEL) today announced that accomplished
biopharmaceutical executive Julie Anne Smith has been elected to the
company’s Board of Directors. Ms. Smith’s appointment took effect on
September 22, 2016.
Ms. Smith has nearly two decades of operational leadership experience in
high growth public, private, startup, and established biopharmaceutical
businesses. She currently serves as president and chief executive
officer of Raptor Pharmaceuticals, a commercial-stage, global innovator
in the development and commercialization of orphan disease therapies.
Ms. Smith previously held key commercial and strategic leadership
positions at companies including Enobia Pharma, Jazz Pharmaceuticals,
and Genzyme.
“I’m delighted to welcome Julie Anne Smith to the Exelixis board of
directors,” said Stelios Papadopoulos, Ph.D., an Exelixis-co-founder and
chairman of the company’s board. “Her deep commercial expertise will
serve Exelixis well as the company continues to execute on the launch of
its latest therapy, CABOMETYX, following regulatory approval in the
United States earlier this year.”
Ms. Smith joined Raptor Pharmaceuticals in 2012, beginning her tenure as
executive vice president and chief operating officer before becoming the
company’s president and chief executive officer in January 2015. From
2008 to 2012, she served as chief commercial officer of Enobia
Pharmaceuticals prior to its acquisition by Alexion. She began her
biopharmaceutical career at Bristol-Myers Squibb, where she was awarded
the President’s Award for Innovation. Smith was named a “40 Under 40”
Executive to Watch by the Boston Business Journal, and received
the “Pinnacle Award for Emerging Executives” from the Boston Chamber of
Commerce. In 2015, the San Francisco Business Times honored
her as one of the "Bay Area’s Influential Women in Business." She holds
a Bachelor of Science degree in biological and nutritional sciences from
Cornell University.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed
to the discovery, development and commercialization of new medicines
with the potential to improve care and outcomes for people with cancer.
Since its founding in 1994, three medicines discovered at Exelixis have
progressed through clinical development to receive regulatory approval.
Currently, Exelixis is focused on advancing cabozantinib, an inhibitor
of multiple tyrosine kinases including MET, AXL and VEGF receptors,
which has shown clinical anti-tumor activity in more than 20 forms of
cancer and is the subject of a broad clinical development program. Two
separate formulations of cabozantinib have received regulatory approval
to treat certain forms of kidney and thyroid cancer and are marketed for
those purposes as CABOMETYX™ tablets (U.S. and EU) and COMETRIQ®
capsules (U.S. and EU), respectively. Another Exelixis-discovered
compound, COTELLIC® (cobimetinib), a selective inhibitor of
MEK, has been approved in major territories including the United States
and European Union, and is being evaluated for further potential
indications by Roche and Genentech (a member of the Roche Group) under a
collaboration with Exelixis. For more information on Exelixis, please
visit www.exelixis.com
or follow @ExelixisInc on Twitter.
Forward-Looking Statement Disclaimer
This press release contains forward-looking statements, including,
without limitation, statements related to: the impact of Ms. Smith’s
commercial expertise on Exelixis’ continued execution on the launch on
CABOMETYX; Exelixis’ commitment to the discovery, development and
commercialization of new medicines with the potential to improve care
and outcomes for people with cancer; Exelixis’ focus on advancing
cabozantinib; and the continued development of cobimetinib. Words such
as “will,” “continue,” “committed,” “focused,” “potential,” or other
similar expressions identify forward-looking statements, but the absence
of these words does not necessarily mean that a statement is not
forward-looking. In addition, any statements that refer to expectations,
projections or other characterizations of future events or circumstances
are forward-looking statements. These forward-looking statements are
based upon Exelixis’ current plans, assumptions, beliefs, expectations,
estimates and projections. Forward-looking statements involve risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in the forward-looking statements as a
result of these risks and uncertainties, which include, without
limitation: the risk that unanticipated developments could adversely
affect the commercialization of CABOMETYX or COMETRIQ; Exelixis’ ability
to conduct clinical trials of cabozantinib sufficient to achieve a
positive completion and risks related to the potential failure of
cabozantinib to demonstrate safety and efficacy in clinical testing;
Exelixis’ dependence on its relationship with Ipsen, including, the
level of Ipsen’s investment in the resources necessary to successfully
commercialize cabozantinib in the territories where it is approved;
Exelixis’ dependence on its relationship with Genentech/Roche with
respect to cobimetinib and Exelixis’ ability to maintain its rights
under the collaboration; Exelixis’ dependence on third-party vendors;
Exelixis’ ability to protect the company’s intellectual property rights;
market competition; changes in economic and business conditions, and
other factors discussed under the caption “Risk Factors” in Exelixis’
quarterly report on Form 10-Q filed with the Securities and Exchange
Commission (SEC) on August 3, 2016, and in Exelixis’ future filings with
the SEC. The forward-looking statements made in this press release speak
only as of the date of this press release. Exelixis expressly disclaims
any duty, obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect
any change in Exelixis’ expectations with regard thereto or any change
in events, conditions or circumstances on which any such statements are
based.
Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered
U.S. trademarks, and CABOMETYX is a U.S. trademark.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160926005526/en/
Contacts:
Investors Contact:
Exelixis, Inc.
Susan
Hubbard, 650-837-8194
Investor Relations and Public Affairs
shubbard@exelixis.com
or
Media
Contact:
For Exelixis, Inc.
Hal Mackins,
415-994-0040
hal@torchcomllc.com
Source: Exelixis, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.